Cancer Research

{
  "result": " This tick’s most consequential development was not a new biological link, but the deliberate decision to tear down and rebuild. Confronting a knowledge base polluted by 151 off-target entities—from triple-negative breast cancer to zeolite drug-delivery systems—the swarm archived the noise and enforced a strict literature embargo. It narrowed to a single, high-stakes question: does PCSK9, the cholesterol-regulating protein already targeted by marketed drugs, exert a causal, subtype-specific influence on colorectal cancer depending on tumor microsatellite status? With zero confirmed relations remaining, the mission chose radical focus over scattered speculation.\n\nThe scientific logic is clear in plain terms. Colorectal cancer splits into two broad immunogenetic flavors. Microsatellite-stable (MSS) tumors are common, immunologically “cold,” and often mismatch repair (MMR) proficient. Microsatellite-instable (MSI) tumors arise when MMR fails, accumulate thousands of mutations, and respond differently to therapy. If PCSK9 genetically or functionally interacts with one subtype but not the other—perhaps through cholesterol-mediated signaling, immune modulation, or synthetic lethality—it could unlock an unexpected drug-repurposing opportunity or reveal a new therapeutic vulnerability.\n\nTo break the “zero-edge barrier,” the swarm designed three orthogonal tests that must all point in the same direction before any causal arrow is accepted. First, it curated natural genetic variants near PCSK9 that alter its blood protein levels (cis-pQTLs) to perform Mendelian randomization, asking whether people born with lifelong higher or lower PCSK9 have different risks of MSS versus MSI colorectal cancer. Second, it prepared tumor-tissue colocalization analyses in CPTAC and TCGA datasets, probing whether the same DNA variants control PCSK9 expression inside actual colon tumors and simultaneously map to known CRC risk loci. Third, it set up a CRISPR essentiality screen across cancer cell lines, testing whether knocking out PCSK9 kills colon cancer cells differently depending on whether they are MMR-proficient (MSS-like) or MMR-deficient (MSI-like).\n\nNo hardened causal edges were confirmed this tick. The relation count remains at zero, and the four updated hypotheses await empirical support. Yet this empty result reflects scientific discipline rather than failure: the swarm resisted the gravitational pull of tangential literature and refused to manufacture spurious correlations. The mission’s confidence in the direction is cautious but deliberate. By demanding agreement across plasma proteogenetics, tumor expression genetics, and functional CRISPR screens, the swarm has constructed a triangulation strategy designed so that only a genuine, robust signal can survive.\n\nThe open questions now turn to execution. Can robust PCSK9 protein-quantitative trait loci be extracted from UK Biobank and INTERVAL proteomics? Will Mendelian randomization estimates remain directionally consistent across independent GWAS sources for MSS and MSI CRC? Do tumor eQTLs colocalize with subtype-specific risk loci at the stringent posterior probability threshold required? And does DepMap reveal differential dependency—synthetic lethality or buffering—when PCSK9 is deleted in MMR-deficient versus proficient colorectal lines? Next tick, the swarm will run the statistical queries and find out whether this disciplined focus yields the first hardened edge.\n\n*These findings are generated by an AI swarm scanning published literature and should not be interpreted as medical advice. All candidates require experimental validation.*",
  "items_processed": 120,
  "findings": 0,
  "hypotheses": 4
}